HUP0101411A2 - A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof - Google Patents
A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereofInfo
- Publication number
- HUP0101411A2 HUP0101411A2 HU0101411A HUP0101411A HUP0101411A2 HU P0101411 A2 HUP0101411 A2 HU P0101411A2 HU 0101411 A HU0101411 A HU 0101411A HU P0101411 A HUP0101411 A HU P0101411A HU P0101411 A2 HUP0101411 A2 HU P0101411A2
- Authority
- HU
- Hungary
- Prior art keywords
- angiotensin
- receptor agonist
- type
- pharmaceutical composition
- pharmaceutical preparation
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 7
- 229940044601 receptor agonist Drugs 0.000 title abstract 7
- 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 title 1
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 5
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 abstract 1
- 101710096334 Type-1 angiotensin II receptor Proteins 0.000 abstract 1
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 abstract 1
- 101710101155 Type-2 angiotensin II receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány egy 2-es típusú angiotenzin II receptoragonistát vagyélettanilag elfogadható sóját tartalmazó gyógyszerkészítményrevonatkozik, amelyben a 2-es típusú angiotenzin II receptoragonista egyszelektív 2-es típusú angiotenzin II receptoragonista vagy egy nemszelektív 2-es típusú angiotenzin II receptoragonista, és amelyben, haa hatóanyag egy nem szelektív 2-es típusú angiotenzin IIreceptoragonista, a hatóanyag egy 1-es típusú angiotenzin IIreceptorantagonistával alkotott kombinációban történő alkalmazásraszolgál. Ezenkívül a találmány tárgyát képezi egy 2-es típusúangiotenzin II receptoragonistának vagy gyógyászatilag elfogadhatósójának az alkalmazása egy olyan gyógyszerkészítmény előállítása,amely gyógyszerkészítmény az emésztőcsatorna olyan kóros állapotainaka kezelésére és/vagy megelőzésére szolgál, amilyen például a dyspepsiavagy a többszörös szervi elégtelenség. ÓThe invention relates to a pharmaceutical composition containing an angiotensin II receptor agonist type 2 or a physiologically acceptable salt thereof, in which the angiotensin II receptor agonist type 2 is a monoselective angiotensin II receptor agonist type 2 or a non-selective angiotensin II receptor agonist type 2, and in which, if the active ingredient is a non-selective type 2 angiotensin II receptor agonist, the active substance is used in combination with a type 1 angiotensin II receptor antagonist. In addition, the subject of the invention is the use of an angiotensin II receptor agonist type 2 or its pharmaceutically acceptable salt for the production of a pharmaceutical composition, which pharmaceutical composition is used for the treatment and/or prevention of pathological conditions of the digestive tract, such as dyspepsia or multiple organ failure. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9800550A SE9800550D0 (en) | 1998-02-24 | 1998-02-24 | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| PCT/SE1999/000262 WO1999043339A1 (en) | 1998-02-24 | 1999-02-24 | A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101411A2 true HUP0101411A2 (en) | 2002-03-28 |
| HUP0101411A3 HUP0101411A3 (en) | 2002-11-28 |
Family
ID=20410283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101411A HUP0101411A3 (en) | 1998-02-24 | 1999-02-24 | A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1066048A1 (en) |
| JP (1) | JP2002504516A (en) |
| KR (1) | KR20010041211A (en) |
| CN (1) | CN1291104A (en) |
| AU (1) | AU755949B2 (en) |
| BR (1) | BR9908188A (en) |
| CA (1) | CA2319123A1 (en) |
| EE (1) | EE200000481A (en) |
| HU (1) | HUP0101411A3 (en) |
| ID (1) | ID26639A (en) |
| IL (1) | IL137990A0 (en) |
| IS (1) | IS5594A (en) |
| MX (1) | MXPA00008172A (en) |
| NO (1) | NO20004215L (en) |
| NZ (1) | NZ506188A (en) |
| SE (1) | SE9800550D0 (en) |
| SK (1) | SK11522000A3 (en) |
| WO (1) | WO1999043339A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
| AU1793101A (en) * | 1999-12-16 | 2001-06-25 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
| AU2002257970B2 (en) | 2001-05-31 | 2007-08-02 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin II agonists |
| AU2006235698B2 (en) | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| DE602006018122D1 (en) | 2005-04-12 | 2010-12-23 | Vicore Pharma Ab | NEW TRICYCLIC ANGIOTENSIN II AGONISTS |
| JP5179349B2 (en) | 2005-04-12 | 2013-04-10 | ヴィコール・ファルマ・アーベー | Novel bicyclic angiotensin II agonist |
| KR101423898B1 (en) * | 2005-12-14 | 2014-07-28 | 암브룩스, 인코포레이티드 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
| US20150119329A1 (en) * | 2012-04-16 | 2015-04-30 | New York University | Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral |
| MX2017010993A (en) | 2015-03-02 | 2018-04-11 | Vicore Pharma Ab | Angiotensin ii receptor agonist for treating pulmonary fibrosis. |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| US20220257698A1 (en) | 2019-08-02 | 2022-08-18 | Lanthiopep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| KR20230004501A (en) | 2020-03-19 | 2023-01-06 | 바이코어 파마 아베 | New Compounds Useful for the Treatment and/or Prevention of Diseases, Disorders, or Conditions Associated with Angiotensin II |
| GB202004094D0 (en) | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006081D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202013721D0 (en) | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| EP4313953A1 (en) | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| AU2022306778A1 (en) | 2021-07-09 | 2024-01-18 | Vicore Pharma Ab | New selective angiotensin ii compounds |
| GB202115303D0 (en) | 2021-10-25 | 2021-12-08 | Vicore Pharma Ab | New formulation |
| WO2023152503A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444067A (en) * | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO1996014060A1 (en) * | 1994-11-04 | 1996-05-17 | Marklund Stefan L | Use of receptor agonists to stimulate superoxide dismutase activity |
| SE9501881D0 (en) * | 1995-05-19 | 1995-05-19 | Astra Ab | New pharmacological use of AII receptor antagonists |
| US5834432A (en) * | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
| SE9502219D0 (en) * | 1995-06-19 | 1995-06-19 | Astra Ab | Novel medical use |
-
1998
- 1998-02-24 SE SE9800550A patent/SE9800550D0/en unknown
-
1999
- 1999-02-24 ID IDW20001909A patent/ID26639A/en unknown
- 1999-02-24 IL IL13799099A patent/IL137990A0/en unknown
- 1999-02-24 AU AU27537/99A patent/AU755949B2/en not_active Ceased
- 1999-02-24 KR KR1020007009295A patent/KR20010041211A/en not_active Application Discontinuation
- 1999-02-24 HU HU0101411A patent/HUP0101411A3/en unknown
- 1999-02-24 EE EEP200000481A patent/EE200000481A/en unknown
- 1999-02-24 SK SK1152-2000A patent/SK11522000A3/en unknown
- 1999-02-24 JP JP2000533135A patent/JP2002504516A/en active Pending
- 1999-02-24 BR BR9908188-1A patent/BR9908188A/en not_active IP Right Cessation
- 1999-02-24 CA CA002319123A patent/CA2319123A1/en not_active Abandoned
- 1999-02-24 WO PCT/SE1999/000262 patent/WO1999043339A1/en not_active Application Discontinuation
- 1999-02-24 NZ NZ506188A patent/NZ506188A/en unknown
- 1999-02-24 MX MXPA00008172A patent/MXPA00008172A/en unknown
- 1999-02-24 CN CN99803230A patent/CN1291104A/en active Pending
- 1999-02-24 EP EP99908017A patent/EP1066048A1/en not_active Withdrawn
-
2000
- 2000-08-21 IS IS5594A patent/IS5594A/en unknown
- 2000-08-23 NO NO20004215A patent/NO20004215L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010041211A (en) | 2001-05-15 |
| BR9908188A (en) | 2000-10-24 |
| NZ506188A (en) | 2003-04-29 |
| HUP0101411A3 (en) | 2002-11-28 |
| EP1066048A1 (en) | 2001-01-10 |
| IS5594A (en) | 2000-08-21 |
| IL137990A0 (en) | 2001-10-31 |
| MXPA00008172A (en) | 2002-06-21 |
| NO20004215D0 (en) | 2000-08-23 |
| NO20004215L (en) | 2000-09-18 |
| SK11522000A3 (en) | 2001-04-09 |
| JP2002504516A (en) | 2002-02-12 |
| AU2753799A (en) | 1999-09-15 |
| EE200000481A (en) | 2002-02-15 |
| CA2319123A1 (en) | 1999-09-02 |
| CN1291104A (en) | 2001-04-11 |
| SE9800550D0 (en) | 1998-02-24 |
| ID26639A (en) | 2001-01-25 |
| AU755949B2 (en) | 2003-01-02 |
| WO1999043339A1 (en) | 1999-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101411A2 (en) | A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof | |
| HUP0301972A2 (en) | Active substance combination containing an opioid having a fentanyl-type structure and ketamine and pharmaceutical compositions containing it | |
| HUP0002316A2 (en) | Flash-melt oral dosage formulation | |
| EA200301165A1 (en) | Drug on the basis of oxycodone | |
| HUP0003848A2 (en) | New use for budesonide and formoterol | |
| HUP9802999A2 (en) | Pharmaceutical composition containing n-propargyl-1-aminoindan | |
| WO2001085257A3 (en) | Opioid antagonist compositions and dosage forms | |
| HUP0004383A2 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| HUP0203176A2 (en) | Solid, oral pharmaceutical composition containing simethicone | |
| HUP0000138A2 (en) | Controlled-release pharmaceutical compositions containing opioid analgetics | |
| HUP0201877A2 (en) | Fast-dispersing dosage forms containing fish gelatin | |
| DE60121301D1 (en) | Flibanserin for the treatment of extrapyramidal movement disorders | |
| HUP0301591A2 (en) | Controlled release hydrocodone compositions | |
| HUP0402492A2 (en) | 5ht4 partial agonist pharmaceutical compositions | |
| HUP0203028A2 (en) | Pharmaceutical formulation containing tolterodine and its use | |
| HUP0203590A2 (en) | Remedies for diseases in association with decrease in bone mass | |
| IL149496A (en) | Pharmaceutical combinations and their use in treating gastrointestinal disorders | |
| BG105173A (en) | Novel salt form of pantoprazole | |
| HUP0103454A2 (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| HUP0301390A2 (en) | Oral pharmaceutical composition containing valsartan | |
| IS7006A (en) | Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds | |
| CA2377174A1 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| HUP0104647A2 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
| HUP0402178A2 (en) | Pharmaceutical composition comprising a 5 hti receptor agonist | |
| HUP0500842A2 (en) | Pharmaceutical dronedarone composition for parenteral administration |